Sleep-wake disorder is a syndrome in which individuals have difficulty falling asleep, staying asleep, or feeling drowsy during the day. Patients with the syndrome wake up too early and are unable to fall back asleep. Insomnia, hypersomnia, sleep apnea, circadian rhythm abnormalities, restless legs syndrome, and other sleep-wake disorders are examples. Individuals suffering from these diseases are frequently dissatisfied with the quality, timing, and quantity of their sleep. Stress, worry, and anxiety are the primary causes of the sleeping disorder. People who suffer from insomnia experience high levels of anxiety and depression. According to the National Sleep Foundation, they are ten times more likely to suffer from clinical depression and 17 times more likely to suffer from clinical anxiety. As a result, sleeping difficulties are linked to stress and depression. The key factor driving market expansion is the increased frequency of insomnia and other problems as a result of quickly changing lifestyles and stressful working situations. According to Insomnia Statistics UK, around 36% of all UK residents struggled to sleep on a weekly basis in 2021.
Segments of the Market
The UK sleep-wake disorder market is divided on the basis of type and treatment. Based on the type, the market is sub-segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm disorders, and others. Based on the treatment, the market is sub-segmented into therapies, medications, and devices.
Recent Developments
The key players in the UK sleep-wake disorder market include KONINKLIJKE PHILIPS N.V., Medtronic plc, Merck & Co. Inc., Pfizer Inc., Sanofi SA, and RESMED Inc., among others. These market players are adopting various strategies to sustain themselves in the competitive market, such as mergers and acquisitions, new product and treatment launches, and investments. Some of the recent developments in the market include-
• In September 2021, Panthera Dental launched precision-made appliances for snoring and sleep apnea in the UK. The company’s custom-made Digital Sleep Apnea Devices (D-SADs) are designed and manufactured using high-precision proprietary CAD/CAM processes. With the launch of this product, the company expanded its Oral Appliance Therapy (OAT) product offering.
• In October 2021, AirAvant Medical introduced a new device called Bongo Rx for the treatment of obstructive sleep apnea (OSA). This device is clinically proven to treat symptoms of mild to moderate Obstructive Sleep Apnea (OSA), including loud snoring, caused by blocked air passages. The device is whisper-quiet compared to the loud droning of traditional CPAP machines, and the user can avoid traditional masks, hoses, electricity, batteries, or bulky headgear, said the company.
• In February 2020, FISHER & PAYKEL HEALTHCARE CORP. LTD. launched the F&P Evora, a new nasal mask for the treatment of obstructive sleep apnea (OSA). The launch of this product increased the product portfolio of the company in the sleep apnea segment, which is anticipated to create a new revenue stream for the company.
Conclusion
Poor sleep patterns and postures, rising stress levels, and lifestyle changes that contribute to CVDs (cardiovascular diseases) are increasing the need for treatment for sleep-wake disorders across the UK. Furthermore, the country's expanding population with behavioral health conditions and increased awareness of sleep disorders are driving market expansion. The UK is regarded as the top country, with over a quarter of Europe's advanced therapy medical product (ATMP) developers situated there, and ATMP clinical trials are increasing year after year. According to the UK government, about 154 trials were taking place in the UK in December 2020, accounting for 12% of all global activities. As a result, such factors will boost demand for medical devices, boosting market expansion.
Additionally, the introduction of wearable technology capable of monitoring sleep patterns as well as other health activities is a critical factor driving new growth potential in the market. The growing demand for wearable sleep monitoring devices for use at home is expected to stimulate development. For improved results, manufacturers of sleep monitoring devices are combining IoT technology into their gadgets, such as rings, watches, and activity trackers. These devices can also measure heart rate variability and blood oxygen saturation, or SpO2, which can show whether a person has irregular rhythms or breathing problems such as sleep apnea. Due to all such factors, the UK sleep-wake disorder market is expected to grow at a significant CAGR during the forecast period, according to OMR Research.